Table 1.
Distribution of patients’ characteristics and prognosis analysis for the establishment of predictive models
| Risk factor | Total Patients, n(%) (n = 798) | None Hemorrhage, n(%)(n = 686) | Hemorrhage, n(%)(n = 112) | P Valuea | P Valueb | OR (95% CI) |
|---|---|---|---|---|---|---|
| Gender, n(%) | ||||||
| Female | 58(7.3) | 52(7.6) | 6(5.4) | Ref | ||
| Male | 740(92.7) | 634(92.4) | 106(94.6) | 0.555 | 0.403 | 1.45(0.61–3.46) |
| Age, n(%) | ||||||
| < 80 | 116(14.5) | 111(16.2) | 5(4.5) | Ref | ||
| ≥ 80 | 682(85.5) | 575(83.8) | 107(95.5) | 0.000 | 0.002 | 4.13(1.65–10.36) |
| BMI, n(%) | ||||||
| < 18.5 | 193(29.4) | 161(28.2) | 32(37.2) | 0.064 | Ref | |
| 18.5–23.9 | 275(41.9) | 237(41.6) | 38(44.2) | 0.410 | 0.81(0.48–1.35) | |
| > 23.9 | 188(28.6) | 172(30.2) | 16(18.6) | 0.059 | 0.020 | 0.47(0.25–0.89) |
| Rivaroxaban dose, n(%) | ||||||
| < 10 mg | 265(33.2) | 233(34.0) | 32(28.6) | 0.115 | Ref | |
| 10 mg | 477(59.8) | 401(58.5) | 76(67.9) | 0.155 | 1.38(0.89–2.15) | |
| > 10 mg | 56(7.0) | 52(7.6) | 4(3.6) | 0.107 | 0.294 | 0.56(0.19–1.65) |
| Antiplatelet drugs, n(%) | ||||||
| no | 387(48.5) | 346(50.4) | 41(36.6) | Ref | ||
| yes | 411(51.5) | 340(49.6) | 71(63.4) | 0.008 | 0.007 | 1.76(1.17–2.66) |
| Hypertension, n(%) | ||||||
| no | 163(20.4) | 141(20.6) | 22(19.6) | Ref | ||
| yes | 635(79.6) | 545(79.4) | 90(80.4) | 0.900 | 0.825 | 1.06(0.64–1.75) |
| Diabetes, n(%) | ||||||
| no | 452(56.6) | 389(56.7) | 63(56.2) | Ref | ||
| yes | 346(43.4) | 297(43.3) | 49(43.8) | 1.000 | 0.928 | 1.02(0.68–1.52) |
| High triglyceride, n(%) | ||||||
| no | 215(26.9) | 188(27.4) | 27(24.1) | Ref | ||
| yes | 583(73.1) | 498(72.6) | 85(75.9) | 0.493 | 0.466 | 1.19(0.75–1.89) |
| High cholesterol, n(%) | ||||||
| no | 481(60.3) | 420(61.2) | 61(54.5) | Ref | ||
| yes | 317(39.7) | 266(38.8) | 51(45.5) | 0.178 | 0.176 | 1.32(0.88–1.97) |
| LDL-cholesterol abnormal, n(%) | ||||||
| no | 321(40.2) | 281(41.0) | 40(35.7) | Ref | ||
| yes | 477(59.8) | 405(59.0) | 72(64.3) | 0.301 | 0.294 | 1.25(0.82–1.89) |
| Lowest_hemoglobin | ||||||
| < 120 | 703(88.1) | 593(86.4) | 110(98.2) | Ref | ||
| ≥ 120 | 95(11.9) | 93(13.6) | 2(1.8) | 0.000 | 0.003 | 0.12(0.03–0.48) |
| Lowest_blood_platelet | ||||||
| < 100 | 21(2.6) | 18(2.6) | 3(2.7) | Ref | ||
| ≥ 100 | 777(97.4) | 668(97.4) | 109(97.3) | 0.973 | 0.973 | 0.98(0.28–3.38) |
| Coronary disease, n(%) | ||||||
| no | 186(23.3) | 170(24.8) | 16(14.3) | Ref | ||
| yes | 612(76.7) | 516(75.2) | 96(85.7) | 0.016 | 0.016 | 1.98(1.13–3.45) |
| Heart failure, n(%) | ||||||
| no | 713(89.3) | 617(89.9) | 96(85.7) | Ref | ||
| yes | 85(10.7) | 69(10.1) | 16(14.3) | 0.187 | 0.181 | 1.49(0.83–2.68) |
| valvulopathy, n(%) | ||||||
| no | 750(94.0) | 646(94.2) | 104(92.9) | Ref | ||
| yes | 48(6.0) | 40(5.8) | 8(7.1) | 0.526 | 0.589 | 1.24(0.57–2.73) |
| PCI, n(%) | ||||||
| no | 734(92.0) | 632(92.1) | 102(91.1) | Ref | ||
| yes | 64(8.0) | 54(7.9) | 10(8.9) | 0.707 | 0.703 | 1.15(0.57–2.33) |
| apoplexy, n(%) | ||||||
| no | 464(58.1) | 413(60.2) | 51(45.5) | Ref | ||
| yes | 334(41.9) | 273(39.8) | 61(54.5) | 0.004 | 0.004 | 1.81(1.21–2.71) |
| Hemorrhage history, n(%) | ||||||
| no | 702(88.0) | 614(89.5) | 88(78.6) | Ref | ||
| yes | 96(12.0) | 72(10.5) | 24(21.4) | 0.002 | 0.001 | 2.33(1.39–3.89) |
| Coagulopathy, n(%) | ||||||
| no | 753(94.4) | 653(95.2) | 100(89.3) | Ref | ||
| yes | 45(5.6) | 33(4.8) | 12(10.7) | 0.024 | 0.015 | 2.38 (1.19–4.75) |
| TT, n(%) | ||||||
| < 15 | 49(6.2) | 42(6.1) | 7(6.2) | 0.377 | Ref | |
| 15–21 | 711(89.4) | 608(89.0) | 103(92.0) | 0.969 | 1.02(0.45–2.32) | |
| > 21 | 35(4.4) | 33(4.8) | 2(1.8) | 0.346 | 0.226 | 0.36(0.07–1.87) |
| APTT, n(%) | ||||||
| < 30 | 22(2.8) | 20(2.9) | 2(1.8) | 0.265 | Ref | |
| 30–45 | 662(83.2) | 573(83.8) | 89(79.5) | 0.557 | 1.55(0.36–6.76) | |
| > 45 | 112(14.1) | 91(13.3) | 21(18.8) | 0.260 | 0.284 | 2.31(0.50–10.65) |
| INR, n(%) | ||||||
| 0.8–1.2 | 689(86.4) | 594(86.7) | 95(84.8) | Ref | ||
| > 1.2 | 108(13.6) | 91(13.3) | 17(15.2) | 0.554 | 0.588 | 1.17(0.67–2.05) |
| Ddimer, n(%) | ||||||
| ≤ 0.5 | 202(25.5) | 180(26.4) | 22(20.0) | Ref | ||
| > 0.5 | 591(74.5) | 503(73.6) | 88(80.0) | 0.194 | 0.157 | 1.43(0.87–2.35) |
| ALT | ||||||
| ≤ 40 | 732(91.7) | 627(91.4) | 105(93.8) | Ref | ||
| > 40 | 66(8.3) | 59(8.6) | 7(6.2) | 0.465 | 0.404 | 0.71(0.31–1.59) |
| AST | ||||||
| ≤ 40 | 751(94.1) | 645(94.0) | 106(94.6) | Ref | ||
| > 40 | 47(5.9) | 41(6.0) | 6(5.4) | 1.000 | 0.796 | 0.89(0.37–2.15) |
| BUN | ||||||
| ≤ 7.5 | 485(60.8) | 424(61.8) | 61(54.5) | Ref | ||
| > 7.5 | 313(39.2) | 262(38.2) | 51(45.5) | 0.145 | 0.141 | 1.35(0.91–2.02) |
| Creatinine | ||||||
| ≤ 110 | 644(80.7) | 556(81.0) | 88(78.6) | Ref | ||
| > 110 | 154(19.3) | 130(19.0) | 24(21.4) | 0.521 | 0.538 | 1.17(0.72–1.90) |
“Ref” is the abbreviation for reference. In individual risk factor, the latter supgroup compares with the “Ref” supgroup yields ORs and their 95% CIs
aP value was calculated by Fisher's exact test or Pearson Chi-Square
bP value was calculated by Logistic Regression